Colorectal cancer (CRC) is known as a common malignant neoplasm worldwide. The role of EGFR/HER2 in CRC is unclear. Afatinib is an irreversible EGFR/HER2 inhibitor. There were few studies of afatinib on CRC. Here, we investigated the protein levels/expressions of HER2 in sera and tumors from CRC patients and the therapeutic effect of afatinib on HER2-overexpressed CRC in vitro and in vivo. The increased HER2 levels were detected in the collected sera and tumors of patients with CRC. The serological HER2 levels were correlated with the tumor HER2 expressions in patients. Afatinib also inhibited the HER2-positive tumor cell growth and caused apoptosis in HER2-overexpressed human colorectal cancer HCT-15 cells but not in low HER2 expressed hum...
We evaluated the ability of the PET imaging agent 89Zr-trastu-zumab to delineate HER2-positive gastr...
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key pla...
Abstract BACKGROUND: Targeting the epidermal growth factor receptor (EGFR) either alone or in comb...
The epidermal growth factor receptor (EGFR) is an important therapeutic target in colorectal cancer ...
Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...
The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous ...
Human epidermal growth factor receptor 2 (HER2) amplification has emerged as a biomarker in colorect...
Trastuzumab, a humanized mouse monoclonal antibody directed against HER2 (Human Epidermal Growth Fac...
Cancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor re...
Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to...
The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, 2 anti-epid...
EGF receptor (EGFR) is elevated in more than 90 % of head and neck squamous cell carcinoma (HNSCC). ...
EGF receptor (EGFR) –mutant lung cancers eventually become resistant to treat-ment with EGFR tyrosin...
Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...
Given the promising control of bladder cancer achieved by combined chemotherapy/radiotherapy with se...
We evaluated the ability of the PET imaging agent 89Zr-trastu-zumab to delineate HER2-positive gastr...
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key pla...
Abstract BACKGROUND: Targeting the epidermal growth factor receptor (EGFR) either alone or in comb...
The epidermal growth factor receptor (EGFR) is an important therapeutic target in colorectal cancer ...
Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...
The epidermal growth factor receptor (EGFR, HER1) is a therapeutic target in head and neck squamous ...
Human epidermal growth factor receptor 2 (HER2) amplification has emerged as a biomarker in colorect...
Trastuzumab, a humanized mouse monoclonal antibody directed against HER2 (Human Epidermal Growth Fac...
Cancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor re...
Cancer treatment, especially that for breast and lung cancer, has entered a new era and continues to...
The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, 2 anti-epid...
EGF receptor (EGFR) is elevated in more than 90 % of head and neck squamous cell carcinoma (HNSCC). ...
EGF receptor (EGFR) –mutant lung cancers eventually become resistant to treat-ment with EGFR tyrosin...
Despite the approval of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs...
Given the promising control of bladder cancer achieved by combined chemotherapy/radiotherapy with se...
We evaluated the ability of the PET imaging agent 89Zr-trastu-zumab to delineate HER2-positive gastr...
Recent studies have led to the recognition of the epidermal growth factor receptor HER3 as a key pla...
Abstract BACKGROUND: Targeting the epidermal growth factor receptor (EGFR) either alone or in comb...